HAVCR2 and neoplasm: In a study about mice with acute myeloid leukemia, it was discovered that the combination of TIM-3-Fc fusion protein and anti-PD-L1 significantly reduced tumor burden at all time points and extended the survival of wild-type mice with high tumor load, compared to single blockade treatment 123.